5 lessons to master clinical data aggregation, transformation, cleaning and analytics to reduce cost, risk and time
MedEvoke, a premier provider of globally aligned, evidence-based scientific narrative development for the biopharmaceutical industry is now poised to broaden its reach with burgeoning new business, and expanded leadership roles will impact the company's scope in key growth areas: servicing global initiatives, and creating brand awareness across the therapeutic landscape.
The partnership is focused on reducing the impact of Virtual Distance and increasing key performance indicators for Stockholm School of Economics Executive Education participants.
Dante Labs, an international leader in bringing affordable Whole Genome Sequencing (WGS) to consumers, is excited to announce the launch of their USD 199/ EUR 169 Black Friday promotion. The promotion is set to bring an easy ability for anybody to put a premium on their health and wellness and that of their loved ones this holiday season.
Partnership will use BenchSci's artificial intelligence to help researchers run successful experiments with the right antibody
Key Opinion Leader spreading awareness of diabetes endorses the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients
Lotus Clinical Research LLC receives private equity backing; expands team with Jeffrey Kinell and Kurt Brykman joining board of directors
Debra Robinson, MBA, MPM, PMP, Sr. Director, Program and Alliance Management at Maverick Therapeutics, joins networking organization
Dry powder inhalers are gaining increasing momentum for drug delivery to the lungs. One of the most used and flexible delivery technologies are capsule-based dry powder inhalers
Nonprofits co-fund feasibility study to test screening tool for 75,000 newborns for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes
Lotus Clinical Research Presented at Pain Therapeutics in San Francisco on Development of Long-Acting Local Anesthetics
Bridge Therapeutics Announces the Addition of Dr. Steve Passik to Its Scientific Advisory Board
Letters from Generation Rx, a powerful look at the mortal dangers for children who have been prescribed anti-depressant drugs.
Bringing a drug from discovery to market is an expensive and time-consuming business. Every drug that fails comes with a cost which could be both reputational and financial. Keeping your development program on track is therefore critical to success.
Companies to collaborate to accelerate the use of standards in the planning stage of clinical trials
Dr. Bob Rappaport joins Bridge Therapeutics' Scientific Advisory Board as its newest member
Parnell delivers 39% revenue growth and a $5.9 million year-to-date improvement in EBITDA as at the third quarter of 2018 compared to the same period in 2017, consolidates the return to profitability, and maintains full-year 2018 guidance at a 35 - 40% increase over 2017 revenue to $26 - $27 million and an EBITDA range of $5.5 - $6.5 million.
Bridge Therapeutics will present a poster presentation at the RESI Conference November 4, 2018, in New York.